Valuation: Inventiva

Market Cap 693M 761M 639M 581M 1.09B 70.51B 1.15B 7.78B 3.09B 38.51B 2.86B 2.8B 121B P/E 2026 *
-4.41x
P/E 2027 * -20x
Enterprise Value 557M 611M 513M 467M 875M 56.6B 920M 6.24B 2.48B 30.91B 2.29B 2.24B 97.02B EV / Sales 2026 *
109x
EV / Sales 2027 * 66.7x
Free-Float
85.61%
Yield 2026 *
-
Yield 2027 * -
1 day-7.27%
1 week-13.42%
Current month-7.70%
1 month+1.21%
3 months-25.79%
6 months-33.75%
Current year-25.60%
1 week 2.86
Extreme 2.865
3.5
1 month 2.86
Extreme 2.865
3.76
Current year 2.57
Extreme 2.57
6.2
1 year 2.57
Extreme 2.57
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
12.7
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 2025-09-30
Director of Finance/CFO 59 2026-04-21
Chief Operating Officer - 2026-08-30
Director TitleAgeSince
Director/Board Member 76 2017-01-31
Director/Board Member 63 2019-05-26
Director/Board Member 52 2024-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Others

Executive/Senior Manager

50,000 0.0262%
1/10/26 Others

General Counsel

25,000 0.0131%
1/10/26 Others

Head of Human Resources

25,000 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
-7.27%-13.42%-18.70%-20.78% 821M
-2.49%-3.76%+50.31%+62.10% 65.42B
-0.63%-2.91%+6.20%+89.22% 58.91B
-2.37%-2.22%+22.87%+82.31% 55.24B
-2.19%-6.15%+11.92%+108.08% 45.66B
-1.89%-7.28%+13.22%+19.74% 41.29B
-0.93%-0.47%+19.73%+43.75% 36.82B
+1.11%-6.44%+130.68%+641.83% 34.48B
-0.80%+0.61%+77.26%+56.26% 32.5B
-2.17%+16.65%-29.21%+474.05% 31.69B
Average -1.96%-2.35%+28.43%+155.65% 40B
Weighted average by Cap. -1.50%-1.66%+31.81%+149.42%

Financials

2026 *2027 *
Net sales 5.13M 5.63M 4.72M 4.3M 8.06M 521M 8.47M 57.49M 22.85M 285M 21.12M 20.67M 893M 3.92M 4.3M 3.61M 3.28M 6.16M 398M 6.47M 43.93M 17.46M 218M 16.14M 15.8M 683M
Net income -160M -176M -147M -134M -251M -16.26B -264M -1.79B -713M -8.88B -659M -645M -27.87B -177M -195M -164M -149M -279M -18.04B -293M -1.99B -791M -9.85B -731M -716M -30.93B
Net Debt -137M -150M -126M -115M -215M -13.91B -226M -1.53B -610M -7.6B -564M -552M -23.84B -432M -475M -398M -362M -680M -43.95B -714M -4.85B -1.93B -24B -1.78B -1.74B -75.34B
Projected Income Statement - Annual - Inventiva
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
87
Date Price Change Volume
26-11-20 €2.935 -7.27% 359,127
26-11-19 €3.165 +8.76% 583,352
26-11-18 €2.910 +0.69% 382,327
26-11-17 €2.890 -8.25% 553,995
26-11-16 €3.150 -7.08% 529,036
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Inventiva
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.935EUR
Average target price
9.256EUR
Spread / Average Target
+215.37%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Inventiva